<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808182</url>
  </required_header>
  <id_info>
    <org_study_id>2016-1196</org_study_id>
    <nct_id>NCT02808182</nct_id>
  </id_info>
  <brief_title>Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)</brief_title>
  <acronym>AGL11</acronym>
  <official_title>Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D): Relative Contribution of Dietary vs Systemic Fatty Acids to Lean Tissue Fatty Acid Fluxes and Oxidative vs Non-oxidative Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <brief_summary>
    <textblock>
      Lipotoxicity-causing fatty acid overexposure and accretion in lean tissues leads to insulin&#xD;
      resistance and impaired pancreatic β-cell function - the hallmarks of T2D - contributing to&#xD;
      associated complications such as heart failure, kidney failure and microvascular diseases.&#xD;
      Proper dietary fatty acid (DFA) storage in white adipose tissue (WAT) is now thought to&#xD;
      prevent lean-tissue lipotoxicity. Using novel Positron-Emission Tomography (PET) and stable&#xD;
      isotopic tracer methods which were developed in Sherbrooke, the investigator showed that WAT&#xD;
      storage of DFA is impaired in people with pre-diabetes or T2D. The investigator also showed&#xD;
      that this impairment is associated with greater cardiac DFA uptake, as well as subclinical&#xD;
      left-ventricular systolic and diastolic dysfunction. Then, It has been found that modest&#xD;
      weight loss in pre-diabetics, after a one-year lifestyle intervention, improved WAT DFA&#xD;
      storage, curbed cardiac DFA uptake, and restored associated left-ventricular dysfunction. It&#xD;
      has been also found that a 7-day low-saturated fat, low-calorie diet raised insulin&#xD;
      sensitivity but did not restore WAT or cardiac DFA metabolism. Whether WAT DFA storage&#xD;
      directly impacts cardiac DFA uptake is not known. Importantly, the investigator recently&#xD;
      uncovered marked sex-specific differences in WAT DFA metabolism. These may explain, at least&#xD;
      in part, sex-related differences in the cardiac DFA uptake, which occurs in pre-diabetes.&#xD;
      Higher spillover of WAT DFA into circulating Non-Esterified Fatty Acid (NEFA) appears to be&#xD;
      linked in women to greater cardiac DFA uptake, as opposed to direct cardiac chylomicron&#xD;
      triglycerides (TG) uptake in men. Here, the investigator will isolate and compare&#xD;
      organ-specific fatty acid uptake occurring postprandially from chylomicron-TG vs. NEFA pools,&#xD;
      as well as the oxidative vs. non-oxidative intracellular metabolic pathways associated with&#xD;
      increased cardiac DFA uptake in pre-diabetic men and women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma NEFA appearance rate</measure>
    <time_frame>2 years</time_frame>
    <description>NEFA appearance will be measured using i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to +360 min, as slightly modified from previous descriptions, using Steele's non steady-state equations. Blood samples to measure plasma palmitate, oleate, linoleate, and total NEFA levels, [7,7,8,8-2H]-palmitate enrichments by GC/MS-MS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac uptake</measure>
    <time_frame>2 years</time_frame>
    <description>will be determined using 11C-palmitate PET/CT. 180 MBq will be administered by bolus injection at postprandial time 90min. After a transmission scan and regional CT (40mA), a 30-min dynamic list-mode PET acquisition will be performed starting at time 90 min on a 18 cm-high thoraco-abdominal segment to include the left cardiac ventricle and most of the liver on a Philips Gemini TOF PET/CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WAT spillover NEFA appearance rates</measure>
    <time_frame>2 years</time_frame>
    <description>WAT spillover NEFA will be determined from oral administration of [U-13C]-palmitate.&#xD;
Blood samples to measure plasma [U-13C]-palmitate and chylomicron-TG [U-13C]-palmitate enrichment by GC/MS-MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oxidative metabolism of NEFA</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed by using 13C-palmitate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac DFA uptake</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed using PET/CT method with oral administration of 18FTHA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>whole-body organ-specific DFA partitioning</measure>
    <time_frame>2 years</time_frame>
    <description>will be determined by whole-body CT (16 mA) followed by PET acquisition of 18FTHA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>will be determined using the HOMA-IR (based on fasting insulin and glucose levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion rate</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed using deconvolution of plasma C-peptide with standard C-peptide kinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-cell function</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAT size</measure>
    <time_frame>2 years</time_frame>
    <description>by biopsy fixed in formalin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal response</measure>
    <time_frame>2 years</time_frame>
    <description>will be determined using a multiplex assay system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein lipase activity</measure>
    <time_frame>2 years</time_frame>
    <description>will be assessed as on frozen 150-mg portions from biopsy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>A0: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A bolus of 180 MBq of [11C]-acetate at time 90min and PET acquisition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A1: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A bolus injection of 180 MBq of [11C]-acetate at time 90min, followed by PET acquisition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B0: PET/scan with [18F]-FTHA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA . PET acquisition at time 90 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1: PET/scan with [18F]-FTHA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>At time 0, a standard liquid meal will be drunk over 20 minutes with 70 MBq of 18FTHA followed by a PET acquisition at time 90 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid</intervention_name>
    <description>oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis</description>
    <arm_group_label>A1: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_label>B1: PET/scan with [18F]-FTHA</arm_group_label>
    <other_name>Niacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[7,7,8,8-2H]-palmitate</intervention_name>
    <description>using i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to +360 min</description>
    <arm_group_label>B0: PET/scan with [18F]-FTHA</arm_group_label>
    <arm_group_label>B1: PET/scan with [18F]-FTHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[U-13C]-palmitate</intervention_name>
    <description>oral administration of [U-13C]-palmitate (0.2 g mixed into the liquid meal) at time 0 min</description>
    <arm_group_label>B0: PET/scan with [18F]-FTHA</arm_group_label>
    <arm_group_label>B1: PET/scan with [18F]-FTHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1</description>
    <arm_group_label>A0: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_label>A1: PET/scan with [11C] palmitate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>liquid meal</intervention_name>
    <description>At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes</description>
    <arm_group_label>A0: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_label>A1: PET/scan with [11C] palmitate</arm_group_label>
    <arm_group_label>B0: PET/scan with [18F]-FTHA</arm_group_label>
    <arm_group_label>B1: PET/scan with [18F]-FTHA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For healthy subjects: fasting glucose &lt; 5.6, 2-hour post 75g Oral Glucose Tolerance&#xD;
             Test (OGTT) glucose &lt; 7.8 mmol/l and HbA1c &lt; 5.8%&#xD;
&#xD;
          -  For subject with glucose intolerance (IGT): 2-hour post 75g OGTT glucose at 7.8-11.1&#xD;
             mmol/l on two separate occasions and HbA1c of 6.0 to 6.4%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  overt cardiovascular disease as assessed by medical history, physical exam, and&#xD;
             abnormal ECG&#xD;
&#xD;
          -  treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to&#xD;
             affect lipid or carbohydrate metabolism (except statins, metformin, and other&#xD;
             antihypertensive agents that can be safely interrupted)&#xD;
&#xD;
          -  presence of liver or renal disease, uncontrolled thyroid disorder, previous&#xD;
             pancreatitis, bleeding disorder, or other major illness&#xD;
&#xD;
          -  smoking (&gt;1 cigarette/day) and/or consumption of &gt;2 alcoholic beverages per day&#xD;
&#xD;
          -  prior history or current fasting plasma cholesterol level &gt; 7 mmol/l or fasting TG &gt; 6&#xD;
             mmol/l&#xD;
&#xD;
          -  any other contraindication to temporarily interrupt current meds for lipids or&#xD;
             hypertension&#xD;
&#xD;
          -  being pregnant&#xD;
&#xD;
          -  not be barren&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>Tenured Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

